Cardiff Oncology, Inc.

NasdaqCM:CRDF 株式レポート

時価総額:US$129.9m

Cardiff Oncology マネジメント

マネジメント 基準チェック /34

Cardiff Oncologyの CEO はMark Erlanderで、 May2020年に任命され、 の在任期間は 4.5年です。 の年間総報酬は$ 1.55Mで、 38.4%給与と61.6%のボーナス(会社の株式とオプションを含む)で構成されています。 は、会社の株式の0.048%を直接所有しており、その価値は$ 62.19K 。経営陣と取締役会の平均在任期間はそれぞれ2.8年と10.2年です。

主要情報

Mark Erlander

最高経営責任者

US$1.5m

報酬総額

CEO給与比率38.4%
CEO在任期間4.5yrs
CEOの所有権0.05%
経営陣の平均在職期間2.8yrs
取締役会の平均在任期間10.2yrs

経営陣の近況

Recent updates

Cardiff Oncology: Some Data Are In; Here's What You Should Know And Look For Next

Nov 07

We're Keeping An Eye On Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate

Oct 09
We're Keeping An Eye On Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate

Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market

Oct 04

We're Hopeful That Cardiff Oncology (NASDAQ:CRDF) Will Use Its Cash Wisely

Jun 19
We're Hopeful That Cardiff Oncology (NASDAQ:CRDF) Will Use Its Cash Wisely

Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)

Mar 09

We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate

Mar 03
We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate

Here's Why We're Watching Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Nov 16
Here's Why We're Watching Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Aug 01
Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Feb 22
Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Cardiff Oncology: 41% Loss In One Day For A Best-In-Class Colorectal Cancer Treatment

Sep 14

Cardiff Oncology: Down But Not Out

Aug 22

Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Jun 20
Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Cardiff Oncology: Upcoming Readouts And Several Green Lights

Jun 07

Cardiff Oncology: Risky Investment

May 19

Cardiff: A Long-Term Biotech To Own Based On Overcoming Cancer Resistance

Mar 01

We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate

Jan 28
We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate

Cardiff: The Pfizer Interest Is Interesting

Dec 15

Circling Back On Cardiff Oncology

Oct 12

Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Aug 26
Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Cardiff Oncology: Current Slump Doesn't Look Right

Jun 14

Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Apr 29
Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

How Much Are Cardiff Oncology, Inc. (NASDAQ:CRDF) Insiders Spending On Buying Shares?

Feb 28
How Much Are Cardiff Oncology, Inc. (NASDAQ:CRDF) Insiders Spending On Buying Shares?

What Type Of Shareholders Own The Most Number of Cardiff Oncology, Inc. (NASDAQ:CRDF) Shares?

Jan 24
What Type Of Shareholders Own The Most Number of Cardiff Oncology, Inc. (NASDAQ:CRDF) Shares?

CEO報酬分析

Cardiff Oncology の収益と比較して、Mark Erlander の報酬はどのように変化したか?
日付総報酬給与会社業績
Sep 30 2024n/an/a

-US$43m

Jun 30 2024n/an/a

-US$41m

Mar 31 2024n/an/a

-US$40m

Dec 31 2023US$2mUS$594k

-US$41m

Sep 30 2023n/an/a

-US$41m

Jun 30 2023n/an/a

-US$40m

Mar 31 2023n/an/a

-US$39m

Dec 31 2022US$2mUS$571k

-US$39m

Sep 30 2022n/an/a

-US$39m

Jun 30 2022n/an/a

-US$38m

Mar 31 2022n/an/a

-US$34m

Dec 31 2021US$4mUS$533k

-US$28m

Sep 30 2021n/an/a

-US$25m

Jun 30 2021n/an/a

-US$23m

Mar 31 2021n/an/a

-US$24m

Dec 31 2020US$1mUS$445k

-US$23m

Sep 30 2020n/an/a

-US$20m

Jun 30 2020n/an/a

-US$20m

Mar 31 2020n/an/a

-US$17m

Dec 31 2019US$853kUS$399k

-US$17m

Sep 30 2019n/an/a

-US$17m

Jun 30 2019n/an/a

-US$16m

Mar 31 2019n/an/a

-US$19m

Dec 31 2018US$909kUS$387k

-US$19m

Sep 30 2018n/an/a

-US$18m

Jun 30 2018n/an/a

-US$18m

Mar 31 2018n/an/a

-US$20m

Dec 31 2017US$1mUS$374k

-US$25m

報酬と市場: Markの 総報酬 ($USD 1.55M ) は、 US市場 ($USD 642.87K ) の同規模の企業の平均を上回っています。

報酬と収益: Markの報酬は、過去 1 年間の会社の業績と一致しています。


CEO(最高経営責任者

Mark Erlander (64 yo)

4.5yrs

在職期間

US$1,547,772

報酬

Dr. Mark Erlander, Ph D., is Chief Executive Officer of Cardiff Oncology, Inc. (formerly known as TrovaGene, Inc.) since May 2020 and was its Chief Scientific Officer March 4, 2013 to April 2020. Dr. Erlan...


リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Mark Erlander
CEO & Director4.5yrsUS$1.55m0.048%
$ 62.2k
James Levine
Chief Financial Officer3.3yrsUS$917.72k0.12%
$ 152.4k
Fairooz Kabbinavar
Chief Medical Officer1.8yrsUS$1.26m0%
$ 0
Tod Smeal
Chief Scientific Officer2.8yrsUS$4.17m0%
$ 0
Elizabeth Anderson
VP of Finance & Administration9.3yrsデータなしデータなし
Brigitte Lindsay
Senior Vice President of Finance1.8yrsデータなしデータなし
Charles Monahan
Senior Vice President of Regulatory Affairs2.8yrsデータなしデータなし

2.8yrs

平均在職期間

61.5yo

平均年齢

経験豊富な経営陣: CRDFの経営陣は 経験豊富 であると考えられます ( 2.8年の平均在職年数)。


取締役

名称ポジション在職期間報酬所有権
Mark Erlander
CEO & Director4.4yrsUS$1.55m0.048%
$ 62.2k
Charles Cantor
Member of Scientific Advisory Boardno dataデータなしデータなし
Gary Pace
Independent Director4.6yrsUS$114.43k1.36%
$ 1.8m
K. Hirth
Member of Scientific Advisory Board10.3yrsデータなしデータなし
Paul Billings
Member of Scientific Advisory Board12yrsUS$35.85kデータなし
Rodney Markin
Independent Chairman of the Board10.8yrsUS$154.43k0.061%
$ 78.9k
Carlo Croce
Member of Scientific Advisory Boardno dataデータなしデータなし
Riccardo Dalla-Favera
Member of Scientific Advisory Board14.6yrsデータなしデータなし
Lale White
Independent Director4.6yrsUS$116.43k0.22%
$ 289.0k
Alberto Bardelli
Member of Scientific Advisory Board10.2yrsデータなしデータなし
Renee Tannenbaum
Independent Director3.4yrsUS$110.43k0.020%
$ 25.4k
Brunangelo Falini
Member of Scientific Advisory Board14.6yrsデータなしデータなし

10.2yrs

平均在職期間

72yo

平均年齢

経験豊富なボード: CRDFの 取締役会 は経験豊富で 経験豊富 です ( 10.2年の平均在任期間)。